| The most common TEAEs reported in the seven patients treated with SGN‐2FF + pembrolizumab were decreased appetite (57%), fatigue (57%), and back pain (57%). |
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.